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ABSTRACT
Esophageal adenocarcinoma (EAC) is a highly aggressive malignancy that 
develops from Barrett’s esophagus (BE), an intestinal metaplasia of the distal 
esophagus. microRNAs (miRNAs), short non-coding regulatory RNAs, are frequently 
dysregulated in BE and are thought to play key roles in the onset of BE and its 
progression to EAC. miRNAs thus have potential diagnostic and prognostic value 
and are increasingly being used as cancer biomarkers. This review summarizes 
the current literature related to miRNAs that are dysregulated in BE within the 
context of Hedgehog, Notch, MAPK, NF kappa-B, Wnt and epithelial-mesenchymal 
transition (EMT) signaling which are thought to drive BE onset and progression. This 
comprehensive analysis of miRNAs and their associated signaling in the regulation 
of BE provides an overview of vital discoveries in this field and highlights gaps in our 
understanding of BE pathophysiology that warrant further investigation.
INTRODUCTION
MicroRNAs (miRNAs) are evolutionarily conserved 
small non-coding RNAs of approximately 18-25 nucleotides 
in length which regulate gene expression by binding to the 
3’-untranslated region (3’-UTR) of target mRNAs to inhibit 
their translation or facilitate their degradation [1]. miRNAs 
have been shown to regulate cell growth, differentiation 
and migration and are frequently dysregulated in cancer. 
Accordingly, there is considerable interest in identifying 
miRNA signatures characteristic of disease stage or 
therapeutic responsiveness. Further, microRNAs are being 
increasingly used clinically as cancer biomarkers because 
they frequently exhibit tissue-specific differences in 
expression, are stable in formalin-fixed tissues and blood 
and may be profiled without the need for an invasive muscle 
biopsy [2, 3]. Serum miRNA biomarkers have particular 
appeal in diseases like Esophageal Adenocarcinoma (EAC) 
which are associated with extended monitoring periods, 
poor early detection, and costly or invasive methodologies.
Esophageal adenocarcinoma (EAC) is the dominant 
histologic type of esophageal cancer in Western society 
and its incidence is increasing. The precursor lesion for 
EAC, termed Barrett’s esophagus (BE), is a metaplastic 
lesion of the distal esophagus in which the normal 
esophageal squamous epithelium is replaced by columnar 
epithelia and goblet cells. Patients with BE are 30–40 
times more likely to develop EAC [4]. Gastroesophageal 
reflux disease (GERD) is the only known risk factor for 
BE, and its prevalence is estimated to be as high as 30% 
in the United States [5]. Currently, white light endoscopy 
(WLE) with biopsy is the standard for diagnosis of BE 
and EAC [6]. The mortality rate in BE patients who 
develop EAC drops by 61% when patients are regularly 
monitored by WLE [7]. However, BE lesions that occur 
at the squamocolumnar junction or in the esophageal 
submucosal glands are not easily identifiable through 
WLE and thus not biopsied [8]. In addition, inflammation 
in the reflux-damaged epithelium can be misdiagnosed as 
dysplasia by WLE with biopsy [9]. Patient anxiety, adverse 
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patient responses to sedatives, and high procedural costs 
also undermine the broad utility of this approach. Since 
the incidence of EAC in BE patients is only 0.55%, the 
cost-effectiveness of surveillance monitoring by WLE and 
biopsy has also been questioned by recent meta-analyses 
[7, 10]. It is therefore necessary to identify BE patients 
most at risk for EAC, allowing BE patients with negligible 
risk to forego the cost, discomfort, and risks of repeated 
endoscopic procedures. Accordingly, there is a need for 
noninvasive serum biomarkers to identify the minority of 
patients at high risk for dysplasia who will benefit from 
surveillance.
BE and EAC research has identified a number of 
potential effectors of BE and EAC development which 
may have potential diagnostic or prognostic value. Proteins 
identified as differentially regulated in BE and EAC 
patients include Trefoil Factor 3, Anterior gradient 2, p16, 
villin, MUC2, and various columnar epithelial cytokeratins 
[11–15]. In addition, the differential expression of p63 
in BE lesions has suggested a connection to normal 
mammalian embryonic development [16, 17]. However, 
none of these proteins or any combination thereof are in 
clinical use as biomarkers for BE or EAC. Fortunately, 
a number of miRNAs have been proposed as potential 
biomarkers for the diagnosis and monitoring of BE [18–
26]. Distinct miRNA signatures associated with GERD 
and BE were first described in 2008, and subsequent 
studies have expanded the list of miRNAs dysregulated in 
BE to at least 105 miRNAs potentially associated with BE 
pathophysiology [19, 20, 22–24, 27–32].
This review summarizes the current literature on 
miRNAs differentially expressed in BE within the context 
of the major signaling pathways they regulate as a means 
of highlighting the functional contribution of miRNAs 
to the onset and progression of BE. miRNAs shown to 
be dysregulated in BE relative to normal esophageal 
tissues are listed as upregulated or downregulated in 
Tables 1 and 2, respectively. Thirteen miRNAs have 
been identified from serum samples with the potential 
to serve as circulating biomarkers of BE. Twenty-four of 
the 105 miRNAs listed were identified as dysregulated in 
BE in more than one study and validated using multiple 
methodologies. Of the remaining 81 miRNAs, 53 were 
shown to be associated with BE in a single study only. 
Of note, miR-127-3p and miR-200a were reported as 
both upregulated and downregulated in BE and are thus 
listed in both Tables 1 and 2. The discrepancy may be due 
to differences in biopsy content (e.g. goblet cell levels), 
microenvironment (e.g. associated GERD) or lesion 
proximity to the squamocolumnar junction for the tissue 
samples evaluated in these studies. Additional testing is 
thus needed to clarify the role played by miR-127-3p and 
miR-200a in BE.
Validated human target genes for each of the BE-
associated miRNA are also listed in Tables 1 and 2. The 
target genes listed were obtained from the Ingenuity 
Pathway Analysis Knowledge Database (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity), a curated 
database of findings from peer-reviewed scientific 
publications. The genes listed are high confidence 
interactions based on validation in human tumor cell lines. 
This list was chosen as a conservative list of functional 
targets for discussion herein, as it is impossible to discuss 
the full list of 10,512 predicted targets identified using 
Partek Genomics Suite (PGS, version 7.17, Target Scan 
7.0 database query). In addition to the target genes listed 
in the IPA database, several additional targets have been 
included based on reports in the literature. These targets 
are underlined in Tables 1 and 2. Although the literature on 
signaling pathways in BE and EAC is extensive and spans 
over six decades, this review only focuses on miRNAs that 
are differentially regulated in BE and regulate Hedgehog, 
Notch, MAPK, NFκB, Wnt, and EMT signaling thought 
to underlie BE onset and progression.
THE SQUAMOUS TO COLUMNAR 
TRANSITION OF BE: MIRNAS IN 
HEDGEHOG AND BMP SIGNALING
BE is characterized by the conversion of normal 
squamous epithelium to an intestinalized columnar 
epithelium resembling an embryonic architecture. The 
molecular basis for this conversion is under debate, but 
it’s believed to arise from a residual esophageal stem cell 
population as an adaptive response to chronic gastric reflux 
[33, 34]. Hedgehog (HH) signaling is thought to play a role 
because it is critical for regulating adult stem and progenitor 
cells during homeostasis and disease. HH signaling is absent 
in the normal adult esophagus but frequently upregulated 
in Barrett’s epithelium, and 96% of EAC patients have 
elevated HH target gene expression [35, 36]. HH signaling 
is stimulated by the ligands Desert/Indian/Sonic Hedgehog 
(D/I/SHH) binding the Patched-1 (PTCH1) receptor. Ligand 
binding to PTCH1 relieves inhibition of Smoothened 
(SMO), a G-protein coupled receptor-like protein, resulting 
in cleavage of the SHH repressor, Suppressor of Fused 
(SUFU) from the GLI transcription factors (Figure 1A). This 
cleavage allows the GLI proteins to initiate transcription of 
HH target genes [37].
miRNA regulation of SHH signaling in BE 
potentially occurs through miR-125b, which targets 
smoothened (SMO) and is downregulated in BE (Table 
1), consistent with the expected increase in Hedgehog-
responsiveness in BE [23]. Overexpression of miR-
125b has previously been observed in lung carcinoma 
cell lines, is associated with poor prognosis in HER2-
positive breast cancer patients and is dysregulated in 
neuronal progenitor tumor cells. Although these studies 
indicate miR-125b has oncogenic potential, its functional 
role in BE has not been investigated [38–40]. miR-194 
targets SUFU and is upregulated in BE tissues [41]. 
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Table 1: MicroRNAs downregulated in Barrett’s esophagus
MicroRNA Sourcea Validated human targetsb Method of Detectionc References
1-3p P NCL, SERP1 9 [27]
10a-5p P HOXA1, HOXD10, KLF4, NF1, 
USF2
3 [27]
106a T APP, ARID4B, HIPK3, MYLIP, 
PAK7, RB1, RUNX1
3,6 [29]
125b T ADAMTS1, ALOX5, ANAPC16, 
ATP6AP1L, B3GALT4, BAK1, 
BMF, BMPR1B, CASP6, CASP7, 
CBLN2, CBX7, CDC25A, CDK6, 
CDKN2A, CEBPG, CYP1A1, 
DICER1, DIO3, E2F3, ELAVL1, 
SMO, ST18, ERBB2, ERBB3, 
KRT19, FAM19A1, GPR160, 
H3F3A/H3F3B, HIST1H4A, 
ID1, ID2, ID3, IGFBP3, IL1RN, 
JARID2, JUN, LIN28A MAN1A1, 
PCDHB10, PERP, PIGR, RBM8A, 
SGPL1, TENM2, TRNAK-UUU, 
TSPAN8, UBE2I, UGT2B15, 
UGT2B17, UGT2B28
10 [30]
125b-2-3p T -- 1 [23]
127-3p P BAG5, BCL6, COA1, GLE1, 
PDIA6, PRDM1, SKI, XBP1
9 [27]
1260b T BCL6, PRDM1, XBP1 3,5 [113]
133a-3p P FSCN1, KLF15, KRT7, PKM, 
RHOA
9 [27]
133b T/P KLF15, PKM, PITX3, PTBP2, 
STK3
3,7 [20]
136-5p P -- 9 [27]
149 T GIT1 4-Feb [22, 24, 31]
149-5p T RAP1A, RAP1B, VAV2 3,5 [113]
154-5p P E2F5 9 [27]
18a-3p T KRAS 3,6 [29]
193b T CCND1, ESR1, ETS1, PLAU 3 [22]
200a T BAP1, CTBP2, CTNNB1 
(B-catenin), CYP1B1, ELMO2, 
ERBB2IP, KLHL20, PTPRD, 
TUBB, WDR37, ZEB1, ZEB2, 
ZFPM2
3,7 [20]
203 T ATM, BIRC5, BMI1, LIFR, 
RAB22A, RUNX2, SCOS1, SIK1, 
ZEB2
2,3,6-8 [18, 20, 23, 24, 29, 
31, 32, 113]
205 T (-3p): none, (-5p): see below 1-4,6,7 [18, 23, 24, 29, 31, 
32]
(Continued )
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The resulting loss of SUFU would lead to increased 
GLI transcriptional activity and HH target expression, 
as observed in BE. miR-378 is also known to target the 
SHH pathway through its targeting of SUFU, a negative 
regulator of SHH signaling, but its downregulation in 
BE (Table 1) is inconsistent with the observed increase 
in SHH signaling [42]. miR-378 is reduced in EAC, 
suggesting that it may have diagnostic or prognostic 
value, but its role in BE physiology remains unclear 
[23, 24].
MicroRNA Sourcea Validated human targetsb Method of Detectionc References
205-5p T ERBB3, INPPL1, MED1, PRKCE, 
VEGFA, ZEB1, ZEB2
3,5 [113]
20b T ARID4B, BAMBI, CRIM1, ESR1, 
HIPK3, MYLIP, PPARG
3,6 [18]
210 T FOXN3, SETD2 1,4 [23, 24]
224-5p T -- 3,5 [113]
23b T MET, PLAU 1,4 [23, 24]
27b T CYP1B1, MMP13, PPARG, ST14, 
WEE1
3,4 [22, 24]
3065-5p T -- 3,5 [113]
31 T DKK1, PRKCE, TIAM1 3,7 [20]
32 T BTG2, BCL2L11, MDM2, TSC1 3,6 [18]
33a-3p T PBX3 1 [23]
378 T SUFU 1,4 [23, 24]
378c T -- 4 [24]
382-5p P MXD1 3 [27]
4462 T -- 4 [24]
543 T NCL 3,6 [18]
708-5p T NNAT 3,5 [113]
744 T BCL2, cMYC, GSK3β, PDCD4, 
PTEN, PTP1B, SFRP1, TLE3
4 [24]
944 T PTP4A1, SIAH1 1,2,3 [23, 31, 113]
99a T (-5p): FGFR3, IGF1R, MTOR, 
RPTOR
4 [24]
99a-3p T -- 1 [23]
Let-7c T ACVR1C, APC, APC2, BCL2L1, 
BMPR1A, BTG2, EIF3J, HMGA2, 
ITGB3, MED28, mir-30, MYC, 
PBX2, PPP1R12B, RTCA, 
SMAD2, SMAD4, STARD13, 
TGFBR1, TRIB1, TRIM71
1,2,3,6 [23]
a Sample source: tissue (T) or plasma (P).
b  Validated human binding targets were obtained from Ingenuity Pathway Analysis Knowledge Database (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity).
c  Evidence (Table 1): 1: TaqMan Human miRNA Card Set v3.0, 2: Illumina microarray, 3: RT-PCR, 4: Affymetrix 
GeneChip miRNA 3.0 array, 5: SOLiD 3 sequencing, 6: OSU custom miRNA microarray chip (OSU_CCC version 4.0), 
7: Agilent Human Microarray V2; 8: two-color competitive hybridization microarray, 9: mirVana miRNA Bioarrays 
(Ambion), 10: Exiqon Serum/Plasma Focus miRNA PCR panel.
Underlines indicate validated targets identified in published literature, but not yet listed in the IPA knowledge base.
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Table 2: MicroRNAs upregulated in Barrett’s esophagus
MicroRNA Sourcea Validated human targetsb Method of 
Detectionc
References
122-5p P AACS, ADAM17, AKT3, ALDOA, ANK2, 
ANXA11, AP3M2, ATP11A, ATP1A2, 
BACH2, BCL2L2, CCNG1, CLDN18, 
CS, DSTYK, DUSP2, EGLN3, ENTPD4, 
FAM117B, FOXJ3, FOXP1, FUNDC2, 
G6PC3, GALNT10, GYS1, MAPK11, MECP2, 
MEP1A, NCAM1, NFATC1, NFATC2IP, 
NUMBL, OSMR, PALM, RAB11FIP1, 
RAB6B, RABIF, SLC7A1, SLC7A11, TBX19, 
TPD52L2, TRIB1, TTYH3, UBAP2, XPO6
9 [27]
127-3p T BAG5, BCL6, COA1, GLE1, PDIA6, PRDM1, 
SKI, XBP1
3 [114]
130b T CYP2C9, CYLD, DICER1, FMR1, IGF-
1, MMP2, NKD2, NRP1, PPARγ, PTEN, 
RUNX3, STAT3
2,3 [31]
133a T FSCN1 1 [23]
135b-3p T -- 3 [114]
136-3p T ADAM9, LHR, SLC7A5 1 [23, 114]
143 T DNMT3A, FNDC3B, KRAS, MAPK7, PLK1, 
PRC1, TOP2A
1,3,8 [23, 32]
145 T FOXO1, FOXO3, MYC, SRF 1,3,4,3 [23, 24, 113]
145-3p T MTDH, UHRF1 1 [23]
146a T ATOH8, BLMH, BRCA1, CCL8, CCNA2, 
CDKN3, CFH, COL13A1, CXCR4, FADD, 
KIF22, IRF5, LTB, MCM10, MCPH1, 
METTL7A, MR1, NFIX, NUMB, PDIK1L, 
PA2G4, PEX11G, PLEKHA4, PBLD, 
POLE2, PRR15, RAD54L, SDCBP2, STAT1, 
TIMELESS, TLR4, TMSB15A, TRIM14, 
UHRF1, VWCE
2,3 [31]
148a T DNMT3B, DNMT1, NR1I2, RPS6KA5 1,4 [23, 24]
151-3p T ATP2a2, TWIST1 4 [24]
151-5p T SMARCA5, TWIST1 4 [24]
153 T BCL2, FOXO1, MCL1 2,3 [31]
15a T BCL2, CHEK1, WEE1 1 [23]
181a T IRF8, MCL1, PBX3 4 [24]
181b T AICDA, BCL2, CDX2, CYLD, ESR1, GATA6, 
GRIA2, NLK, PLAG1, TCL1A, VSNL1
4 [24]
187-3p T -- 3 [113]
191 T PTEN, ZEB2 4 [24]
192 T (-3p): SCD, ALDH3A2 2,3,4,6,7 [18–20, 24, 29, 31]
192-5p T DHFR, DTL, TYMS 2,3,5 [31, 113]
194 T SUFU, (-3p): AP-1, FOSL1 2,3,4,7 [19, 20, 24, 31]
194-5p S/T AKT2 2,3,5,9 [27, 31, 113]
195 T DHFR, DTL, TYMS 1,4 [23, 24]
(Continued )
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MicroRNA Sourcea Validated human targetsb Method of 
Detectionc
References
196a T (-3p): LSP1, NRP2, TYMS, ZG16 2,3,4 [24, 31] [19]
196a-5p T ANXA1, COL1A1, HOXA7, HOXB8, 
HOXD8, HOXC8, IKBKB, KRT5, S100A9, 
SPRR2C
3,5 [113]
196b T BCL2, cMYC, GATA6, HOXA9, IGF2BP1, 
TGFBR2
2,3,4 [31] [24]
1974 S -- 9 [27]
199a-5p T ALOX5AP 1 [23, 114]
200a T BAP1, CTBP2, CTNNB1, CYP1B1, ELMO2, 
ERBB2IP, KLHL20, PTPRD, TUBB, WDR37, 
ZEB1, ZEB2, ZFPM2
2,3 [31]
200b T BAP1, CTBP2, CTNNB1, CYP1B1, ELMO2, 
ERBB2IP, KLHL20, PTPRD, TUBB, WDR37, 
ZEB1, ZEB2, ZFPM2
2,3,4 [24, 31]
200c T ERRFI1, FHOD1, MARCKS, NOG, PLCG1, 
PPM1F, PTPN13, ZEB1, JAG1
10 [30]
21 T ACTA2, APAF1, BMPR2, BTG2, C8orf44-
SGK3/SGK3, CDC25A, CDK6, CDKN1A, 
CFL2, CLU, FAM3C, FAS, FBXO11, GLCCI1, 
HIPK3, IL6R, IRAK1, JAG1, LRRFIP1, 
MARCKS, MTAP, MYD88, NFIB, PDCD4, 
PDCD4, PIK3R1, PRRG4, PTEN, RECK, 
RP2, SERPINB5, SESN1, SLC16A10, SOCS5, 
SOD3, SOX5, TGFBR2, TIAM1, TIMP3, TNF, 
TPM1
1,2,3,4 [19, 22–24, 31]
214 T ING4, PTGS2 (COX2), PTEN 4 [24], -5p [114]
215 T DHFR, DTL, TYMS 1,2,3,6,8 [18, 23, 29, 31, 32]
223 T AR, CYB5A, FBXW7, GFPT1, HMGCS1, 
IRS1, KIF1BP, LMO2, MT1E, NFIA, PARP1, 
RHOB, SCARB1, SLC11A2, SLC39A1, 
SMARCD1, SP3, STMN1, STMN1
1 [23], -5p [114]
223-5p T IL-6, STAT-3, TP63 1 [23]
25 T MDM2, TSC1, ZNF512B 1,3,4,5 [23, 24, 113]
26a-1-3p T -- 1 [23]
28-5p T GPX2, IGF1, MAD2, RAP1B, SEPSH2 4 [24]
29c T -- 1 [23]
29c-3p T CDC42, COL1A1, COL1A2, COL3A1, 
COL4A1, COL4A2, COL15A1, DNMT3A, 
DNMT3B, FBN1, LAMC1, PIK3R1, SPARC, 
SRSF10, TDG
1 [23]
301b T BIM, NDRG2, TP63 1 [23]
30a-3p T CDK6, CYR61, FMR1, SLC7A6, THBS1, 
TMEM2, TUBA1A, VEZT, WDR82
1 [23]
338-3p T UBE2Q1 1,3,5 [23, 113]
3613-5p T -- 2,3 [31]
375 T KIAA1524, YAP1, YWHAZ 4 [24]
(Continued )
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Ectopic HH signaling blocks the expression of 
Noggin, an inhibitor of the BMP (bone morphogenic 
protein) pathway, leading to increased BMP4 signaling 
and resulting in failed stratification of the columnar 
epithelium and a BE phenotype [43]. BMP signaling 
promotes expression of stem cell genes while suppressing 
genes involved in cell death. BMP signaling is increased 
in BE and is thought to function in the maintenance of 
epithelial stemness in BE [44]. BMP signaling occurs 
through the receptor-mediated SMADs (SMAD1/5/8) 
which associate with the co-mediator SMAD4 and are 
translocated to the nucleus to activate BMP target gene 
expression [45]. Increased bile acids associated with 
GERD and BE have been shown to directly stimulate HH 
signaling and increase expression of PTCH1 and BMP4 in 
the BE stroma [36]. Other downstream targets of elevated 
HH in BE include SOX9, a transcription factor important 
in intestinal crypt development, and FOXA2, a driver of 
MicroRNA Sourcea Validated human targetsb Method of 
Detectionc
References
376c-3p T -- 3 [114]
409-3p T AKT1, ANG, Beclin-1, cMET, CTNND1, 
GAB1, PHF10, ZEB1
1 [23, 114]
424-5p T ANLN, ATF6, CCND1, CCNE1, CCNF, 
CDC14A, CDC25A, CHEK1, FGF2, 
FGFR1, KIF23, GALNT13, MAP2K1, mir-9, 
MGAT4A, NFIA, OGT, PLAG1, SPI1, WEE1
1,2,3 [23, 31, 114]
4417 T -- 4 [24]
450b-5p T MET, SOX2 1 [23]
451a S ABCB1, AKTIP, FBXO33, MIF 9 [27]
487b T CDKN2AIP, MAP2K4 3 [22]
492 T CD147, PTEN, RETN, SOX7 1 [23]
497 T BCL2, BDNF, E2F3, FRA1, HIF1a, HDGF, 
KCa3.1, mTOR, NRDP1, SIRT4, SLUG, 
SMAD7, VEGFA, VEGFR2, YAP1
1 [23]
501-5p T CYCLD, DKK1, GSK3β, NKD1 1 [23]
503 T AGO1, ANLN, ATF6, CCND1, CCNE1, 
CCNE2, CCNF, CDC14A, CDC25A, CDKN1A, 
CHEK1, FGF2, FGFR1, mir-9, WEE1
4 [24]
542-3p T ILK, PTGS2 (COX2) 1 [23]
548b-3p T -- 3,6 [18]
551b-3p T -- 3,5 [113]
618 T XIAP 1 [23]
625 T (-3p): MAP2K6, SCAI; (-5p): NTRK3 2,3 [31]
642 T -- 1 [23]
7 T EGFR, IRS1, IRS2, KMT5A, NEFM, PAK1, 
RAF1, SLC3A2, SNCA
2,3 [31]
95-3p S CELF2, CCND1 9 [27]
Let-7 T MYC 4 [24]
a Sample source: tissue (T), plasma (P) or serum (S).
b  Validated human binding targets were obtained from Ingenuity Pathway Analysis Knowledge Database (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity).
c  Evidence (Table 2): 1: TaqMan Human miRNA Card Set v3.0, 2: Illumina microarray, 3: RT-PCR, 4: Affymetrix 
GeneChip miRNA 3.0 array, 5: SOLiD 3 sequencing, 6: OSU custom miRNA microarray chip (OSU_CCC version 4.0), 
7: Agilent Human Microarray V2, 8: two-color competitive hybridization microarray; 9: Exiqon Serum/Plasma Focus 
miRNA PCR panel, 10: mirVana miRNA Bioarrays (Ambion).
Underlines indicate validated targets identified in published literature, but not yet listed in the IPA knowledge base.
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the intestinal mucin MUC2 [46, 47]. Collectively, these 
studies suggest bile reflux elevates HH signaling which 
induces an intestinal phenotype through BMP4, SOX9 and 
FOXA2 in the esophageal squamous epithelium.
The elevated BMP signaling observed in BE is 
potentially mediated by miR-200c, miR-130 and let-7c 
(Figure 1B). miR-200c is upregulated in BE (Table 2) and 
directly targets and inhibits Noggin expression, and thus 
is a potential contributor to the enhanced BMP signaling 
observed in BE [30, 48]. Let-7c is downregulated in 
BE and may contribute to increased BMP signaling by 
increasing both SMAD2 and SMAD4 levels [23, 49].
THE SQUAMOUS TO COLUMNAR 
TRANSITION OF BE: MIRNAS AND 
NOTCH SIGNALING
In the normal esophagus, Notch signaling is 
strongest in the basal layer of stratified epithelia, where 
it maintains normal differentiation and stratification [50]. 
Signaling is induced when Delta-like ligand 1/2 (DLL1/2) 
or Jagged1/2 (JAG1/2) interacts with the NOTCH1/2 
receptor, resulting in cleavage of its intracellular domain 
(NICD) (Figure 2A). NICD combines with recombination 
signal binding protein for immunoglobulin kappa J region 
(RBPJ) and Mastermind-like proteins (MAML), forming 
a transcriptional complex [51]. JAG1 is frequently 
downregulated in BE resulting in the loss of Notch 
signaling and epithelial stratification [52]. Interestingly, 
Notch signaling is elevated during the progression of 
BE to EAC suggesting that miRNA regulation of Notch 
signaling may be disease stage-dependent [53].
As shown in Table 2, miR-21, miR-200c, miR-122-
5p and miR-146a are upregulated in BE and target the 
Notch pathway (Figure 2A) [24, 27, 30]. miR-21 and miR-
200c target JAG1 resulting in loss of NOTCH activation, 
consistent with a role in mediating the squamous to 
columnar transition in BE [54, 55]. miR-122-5p is also 
upregulated in BE and targets the Notch agonist ADAM17, 
potentially reducing the ADAM17-mediated cleavage of 
NOTCH and downstream signaling [27, 56, 57]. MiR-
146a is upregulated in BE and has been shown to target 
the Notch antagonist NUMB, raising the possibility that 
miR-146a is involved in re-establishing Notch signaling 
upon dysplastic progression of BE [53, 58]. Finally, miR-
200a inhibits the C-terminal binding protein 2 (CTBP2) 
which serves as a co-repressor of RBPJ [59]. Loss of miR-
200a would lead to increased CTBP2 levels and could 
account for the inhibition of Notch signaling expression 
in BE, but there are conflicting reports on how miR-200a 
expression is altered in BE.
Figure 1: Maintenance of stemness in BE by Hedgehog and BMP signaling. (A) Upregulation of Hedgehog signaling in BE 
is thought to occur as an adaptive response to chronic bile acid exposure in GERD. Loss of miR-125b and increased expression of miR-
194 in BE would de-repress Smoothened and SUFU respectively and serve to facilitate SHH signaling. (B) Increased BMP signaling in 
BE is thought to result from a loss of the HH target Noggin, potentially a result of elevated miR-200c expression. Loss of Let-7c may also 
contribute to increased BMP signaling. Items shown in red and green are upregulated and downregulated in BE, respectively.
Oncotarget8187www.impactjournals.com/oncotarget
INTESTINALIZATION OF THE 
COLUMNAR EPITHELIUM: MIRNAS IN 
CDX2 AND MAPK SIGNALING
The Caudal Type Homeobox 2 (CDX2) transcription 
factor drives the expression of intestinal genes and those 
involved in goblet cell differentiation and is upregulated 
in BE (Figure 2) [60]. Increased CDX2 levels in BE are 
promoted by reduced Notch signaling, unconjugated bile 
acids in GERD, activation of p38, and by the inactivation 
of ERK signaling [17, 61–63]. Although increased 
activation of the ERK Mitogen Associated Protein Kinase 
(MAPK) has been observed in GERD patients without 
BE, reduced phosphorylation of the ERK is frequently 
observed in Barrett’s epithelium relative to the normal 
squamous epithelium suggesting that ERK activation 
by gastric acid is abrogated in BE [61, 64, 65]. ERK 
inactivation in BE is thought to promote the observed 
increase in CDX2 transcriptional activity and promote the 
terminal differentiation of intestinal epithelial cells [66].
As shown in Table 2, several miRNAs upregulated 
in BE are predicted to target the ERK pathway (Figure 
2B). ERK is activated by the binding of growth factors 
(EGF, FGF) to their receptors (EGFR, FGFR). EGFR 
is targeted by miR-7, while miR-424 and miR-503 
target both FGF and the FGFR [67, 68]. Reduced ERK 
activation occurring as a consequence of EGFR and FGFR 
inhibition by these miRNAs potentially explains the 
observed reduction in signaling through the RAF-RAS-
MEK-ERK kinase cascade in BE [69]. Within the pathway 
itself, upregulation of miR-143 and miR-7 observed in BE 
may also contribute to the loss of ERK signaling through 
downregulation of KRAS and RAF1, respectively [70, 71].
Of note, increased MAPK signaling through JNK 
and p38 is believed to contribute to the intestinalization 
in BE through induction of activated AP-1, a transcription 
complex that includes JUN and FOS heterodimers [72]. 
AP-1 is responsible for the expression of MUC5AC in BE 
lesions, as well as several genes involved in inflammation 
and carcinogenesis [73–75]. miR-21 is known to inhibit 
the TNF ligand and the TGFβ receptor, upstream activators 
Figure 2: Loss of epithelial stratification and intestinalization of the columnar epithelium by Notch, CDX2 MAPK 
signaling. (A) Loss of NOTCH signaling in BE is thought to occur as a consequence of diminished JAG1 ligand expression which may result 
from an upregulation of miR-200c and miR-21 in BE. Enhanced miR-122-5p expression may abrogate NOTCH signaling through repression of 
the NOTCH agonist ADAM17. Loss of miR-200a potentially contributes to NOTCH suppression by alleviating repression of the co-repressor 
CTBP2 and leading to destruction of the NICD/RBPJ transcriptional complex. Loss of NOTCH signaling reduces HES1 expression, relieving 
ATOH1 inhibition and leading to increased CDX-2 and MUC2 levels observed in BE. (B) Loss of ERK signaling in BE may be explained by 
an upregulation of several BE-associated miRNA, including miR-424, miR-503, mir-7, miR-143 and miR-7. Loss of ERK has also been linked 
to increased CDX2 levels. Loss of miR-21 and miR-125b may contribute to increased p38 and JNK kinase levels observed in BE. Asterisk 
indicates miRNA with unclear regulation in BE. Items shown in red and green are upregulated and downregulated in BE, respectively.
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of p38 and JNK, respectively. miR-21 is downregulated in 
BE, consistent with an increase in both signaling cascades 
and consistent with a role for miR-21 in BE (Table 1) [24]. 
miR-125b targets cJUN and is also downregulated in BE, 
thus potentially leading to an increase in other factors 
downstream of JNK (Table 1) [30, 76].
DYSPLASTIC PROGRESSION TO EAC: 
MIRNAS IN WNT SIGNALING
Wnt signaling is critical for normal intestinal 
development and homeostasis (Figure 3), and is thought 
to play a critical role in the dysplastic progression of 
BE to EAC [77]. Wnt signaling is normally active in 
the esophagus after its separation from the foregut, but 
is absent in BE due, in part, to an upregulation of the 
WNT inhibitor Dickkopf-related protein 1 (DKK1) [78, 
79]. Increased DKK1 prevents recruitment of glycogen 
synthase kinase-3β (GSK3β) and Adenomatosis Polyposis 
Coli (APC) to the cell membrane, thus facilitating 
β-catenin phosphorylation and degradation. The resulting 
loss of nuclear β-catenin reduces transcription of Wnt 
target genes as observed in BE [80]. By contrast, increased 
nuclear β-catenin is observed in high-grade dysplasia 
suggesting that canonical WNT/β-catenin activation does 
not contribute to the onset of BE but instead promotes the 
dysplastic progression of BE to EAC [78, 81]. SOX17, 
a negative regulator of WNT, is progressively lost in the 
progression from normal mucosa to EAC, but it remains 
unclear whether SOX17 directly contributes to the 
metastatic progression to EAC [82]. miR-141 has been 
shown to downregulate SOX17 expression in esophageal 
cancer cell lines, thus potentially activating Wnt signaling 
to promote esophageal tumorigenesis, but miR-141 
dysregulation in BE or EAC has not yet been reported [82].
Loss of WNT activation in BE is potentially linked 
to a downregulation of miR-31, miR-744, let-7c and miR-
200a in BE, although the contribution of these miRNAs to 
the progression to EAC remains unclear (Table 1). miR-31 
directly targets the Wnt inhibitor DKK1, thus providing a 
possible explanation for the observed increase in DKK1 
levels in BE [20, 83]. The subsequent elevation of miR-
31 in EAC relative to BE suggests a potential role for 
miR-31 in the progression to EAC in a manner similar 
to its role in lung cancer where it is known to enhance 
proliferation and tumorigenicity through upregulation 
of Wnt signaling [20, 84]. miR-744 has also been 
shown to directly target several negative modulators of 
Wnt/β-catenin signaling, including glycogen synthase 
kinase 3β (GSK3β) [15]. The observed loss of miR-
744 is thus consistent with diminished Wnt signaling in 
BE, but unlike its role in driving WNT activation and 
tumorigenicity through increased expression in pancreatic 
Figure 3: Dysplastic progression to EAC through WNT activation. WNT signaling is lost in BE but elevated during dysplastic 
progression to EAC. Loss of WNT signaling in BE is thought to occur as a consequence of elevated DKK1 levels, potentially resulting 
from miR-31 loss. Subsequently, loss of let-7c, miR-125b and miR-200a and increased miR-181b levels may contribute to WNT activation 
in EAC by facilitating accumulation of nuclear β-catenin and activation of WNT target genes. Asterisk indicates miRNA with unclear 
regulation in BE. Items shown in red and green are upregulated and downregulated in BE, respectively.
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cancer, miR-744 is instead reduced in EAC calling its role 
in dysplastic progression to EAC into question [85]. Loss 
of let-7c potentially leads to an increase in APC levels and 
stabilization of the destruction complex and may serve to 
limit β-catenin transactivation in BE [24, 38, 49]. Like 
miR-744, Let-7c is subsequently reduced in EAC [21].
A number of BE-related miRNAs have targets in 
the Wnt signaling cascade and potentially play a role in 
promoting Wnt signaling during its metastatic progression 
toward EAC. Upregulation of miR-181b in BE decreases 
Nemo Like Kinase (NLK), alleviating repression of 
TCF and facilitating TCF/LEF binding to Wnt-response 
elements and increasing Wnt target gene expression (Table 
2) [24, 86]. Although a definitive link to BE or EAC has 
not been established, miR-181b, shown to increase tumor 
metastasis in a mouse model of non-small cell lung 
carcinoma (NSCLC), is upregulated in both metastatic 
human NSCLC and breast cancer and is regulated by 
CDX2 [87, 88]. miR-501-5p may similarly activate Wnt 
signaling by inhibiting GSK3β, thus promoting malignant 
behavior in EAC as previously observed in gastric cancer 
[89]. Additionally, loss of miR-200a in meningiomas was 
shown to promote tumor growth by directly targeting beta-
catenin (CTNNB1), but its role in BE remains unclear due 
to conflicting reports on the dysregulation of miR-200a 
[20, 31, 90].
Several other miRNAs differentially regulated 
in BE appear to regulate cell cycle progression through 
modulation of downstream validated Wnt targets (Tables 
1 and 2). miR-145 and let-7 target c-MYC, miR-125b 
targets c-Jun, and miR-424 and miR-503 target cyclinD1 
[76, 91–94]. These miRNAs appear to have contrasting 
functions, thus further studies into their roles in mediating 
BE-physiology are needed.
ELEVATED NF-ΚB SIGNALING AND 
EMT IN EAC
Although not normally expressed in squamous 
esophageal epithelium, NF-κB signaling is elevated in a 
variety of cancers, inflammatory diseases, and is increased 
in GERD, BE, and EAC tissue relative to adjacent normal 
squamous epithelium [95]. NF-κB is elevated in 40% of 
BE patients, and its expression correlates strongly with 
dysplastic progression to EAC [96, 97]. Unconjugated bile 
acids induce NF-κB signaling, increasing the expression 
of a variety of downstream pro-inflammatory mediators 
frequently overexpressed in BE and esophageal cancer 
cell lines [96, 98, 99]. miR-21, miR-130b and miR-
181b are upregulated in BE and are known to positively 
regulate NF-κB signaling (Figure 4A). miR-21 targets 
Figure 4: Elevated NF-κB signaling and EMT in EAC. (A) NF-κB signaling is elevated in GERD, BE and EAC, potentially due to 
increased miR-130b, miR-181b or miR-501-5p-mediated suppression of the NF-κB suppressor CYLD. BCL2 and COX2 are elevated in BE as 
a result in increased NF-κB signaling. The miRNA which target these mRNA (marked with an asterisk) are upregulated and inconsistent with a 
role in BE or EAC. (B) EMT is increased during the MDC progression to EAC. The miR-200 family of miRNA and miR-409-3p are increased in 
BE and thus potentially function to suppress ZEB1 and ZEB2 during early stages. miR-200 family miRNAs are subsequently suppressed in EAC, 
thus correlating with increased ZEB1 and ZEB2 and thus EMT. Asterisk indicates miRNA with unclear regulation in BE. Double asterisk indicates 
miRNA regulation inconsistent with a role in BE or EAC. Items shown in red and green are upregulated and downregulated in BE, respectively.
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PTEN, which results in an increase in AKT signaling 
and downstream NF-κB [100]. miR-130b, miR-181b and 
miR-501-5p are known to drive inflammation through 
NF-κB by targeting the Ubiquitin-Specific-Processing 
Protease (CYLD), a known NF-κB suppressor [100–
102]. Mechanistic studies into the role(s) played by these 
miRNAs in regulating NF-κB signaling in BE and EAC 
are needed.
B-Cell CLL/Lymphoma 2 (BCL2) and Cytochrome 
C Oxidase II (COX2), both downstream NF-κB effectors, 
are upregulated and associated with apoptotic resistance in 
BE [103, 104]. Several BE-related miRNAs which target 
these genes are upregulated (indicated in Figure 4A with 
a double asterisk). Upregulation of these miRNAs (shown 
in Figure 4A) would suppress NF-κB signaling and is not 
consistent with the observed increase in NF-κB signaling 
BE or EAC. However, the corresponding miRNA mimics 
may hold therapeutic potential by increasing apoptosis in 
BE lesions.
In the transition from BE to invasive EAC, the 
Epithelial-Mesenchymal transition (EMT) is a prerequisite 
for tumor invasion (Figure 4B). EMT, a process by 
which epithelial cells become migratory and invasive, 
is regulated by several transcription factors including 
ZEB1/2 and SNAIL1/2 [105]. The miR-200 family of 
miRNAs, including miR-200a, miR-200b and miR-200c 
are known to regulate EMT through inhibiting ZEB1/2, 
but a role in the BE to EAC progression has not been 
clarified. These miRNAs are upregulated in BE and 
suppressed in EAC, consistent with a role in promoting 
EMT during the dysplastic progression to EAC [106, 107].
CONCLUSIONS
While a number of the key regulators underlying BE 
pathophysiology and its progression to EAC have been 
identified, effective protein and miRNA biomarkers for BE 
remain poorly defined. As regulators of a third of all human 
genes, miRNAs have potential beyond clinical biomarkers 
and may be used to elucidate the interactions among 
signaling pathways in BE pathogenesis, as well as other 
human diseases. This review strived to provide mechanistic 
context by correlating the key regulatory proteins involved 
in BE with miRNAs that are differentially expressed in BE. 
Using IPA, we were able to correlate miRNAs dysregulated 
in BE to the intestinalization of esophageal tissue through 
upregulation of Hedgehog signaling, and in the maintenance 
of epithelial stemness in BE through upregulation of 
BMP4 signaling. We further elaborated on the potential 
mechanisms by which dysregulated miRNAs downregulate 
NOTCH and ERK signaling while upregulating JNK and 
p38 signaling to induce mucin expression and maintain 
intestinal identity. We identified miRNAs which potentially 
play a role in regulating proliferation and tumorigenicity 
by suppressing WNT signaling in BE and enhancing WNT 
signaling during the dysplastic progression to EAC. We 
illustrate how miRNAs which are dysregulated in GERD, 
BE and EAC support increased NFkB signaling and 
expression of pro-inflammatory mediators and apoptotic 
resistance. Finally, identification of several miRNAs which 
affect EMT signaling were correlated to the metastatic 
progression to EAC.
Few studies have compared miRNA signatures 
from tissue and serum, so it is difficult to predict 
whether circulating miRNA levels accurately reflect 
those from esophageal biopsies [108]. Of the 105 BE-
related miRNAs discussed in this review, only 13 were 
characterized from serum or plasma. Additional testing 
will be required to determine if the remaining miRNAs 
tested from tissue are part of the circulating miRNA 
signature of BE. Strong correlations between serum and 
tissue miRNA levels observed in breast and non-small cell 
lung cancer signatures is promising, but additional studies 
are needed in order to determine if BE-related miRNAs 
identified from tissue samples (Tables 1 and 2) serve as 
effective circulating biomarkers [109, 110]. Bansal et al. 
utilized muscle biopsies from BE patients with or without 
dysplasia to identify dysregulation of miR-15b, miR-21, 
miR-203, miR-485-5p and let-7a as collectively predictive 
for dysplasia in BE [26]. Determining whether expression 
of these miRNAs is similarly altered in serum would 
provide an initial gauge of how effectively serum miRNA 
profiles reflect those in BE lesions.
Transduction of human cancer cells with lentiviral 
vectors encoding for antisense oligos to selected miRNAs 
has been shown to reduce pancreatic tumor burden 
in SCID mice [111]. Accordingly, it is our hope that 
knockdown of key miRNAs overexpressed in BE (Table 2) 
may hold therapeutic potential. In particular, knockdown 
of miR-122-5p, miR-21, miR-200c, miR-7, miR-143, 
miR-503, mir-424 and miR-181b are of particular interest 
due to their functional ties to key regulators of BE 
progression in the NOTCH, MAPK, EMT, Wnt, NFκB 
and EMT pathways (Figures 1–4).
While this review focused on the downstream 
targets of miRNAs known to be dysregulated in BE, it 
should also be noted that these same miRNAs may be 
used to predict potential upstream master regulators which 
mediate BE lesion formation. At least 12 of the 98 BE-
related miRNAs are direct targets of p53, suggesting that 
p53 may be causal in some fashion. Specifically, miR-
143, miR-145, miR-191, miR-192, miR-22, miR-25, 
miR-661 and let-7 are upregulated in BE and validated 
targets of p53. miR-149, miR-210, miR-32 and miR-378 
are downregulated by p53. A role for p53 in BE has not 
been clearly defined, but elevated p53 expression (>5%) is 
associated with progression to advanced neoplasia [112].
Identification of clinically reliable early miRNA 
biomarkers of BE will require extensive validation and 
a deeper understanding of the cellular signaling events 
which drive BE development. Of the miRNAs discussed 
in this review, it remains unclear which miRNAs have the 
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potential to serve as biomarkers specific to BE and which 
are broad spectrum cancer biomarkers. Further studies into 
the mechanisms by which circulating miRNAs become 
differentially expressed are needed to identify those 
miRNAs of real clinical importance. A number of technical 
challenges remain which have hindered current efforts at 
identifying miRNA biomarkers including low miRNA 
yield from serum samples, lack of suitable endogenous 
miRNA controls, and a lack of strategies to deal with 
normal variation in circulating miRNA levels. Improved 
early detection of BE and other cancers will only occur by 
overcoming these technical challenges and by obtaining a 
more detailed understanding of miRNA signaling networks.
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